On Thursday, US President Donald Trump signed new tariffs targeting foreign-made pharmaceuticals and restructured existing metal duties as part of his ongoing trade agenda. The 100% tariff on patented drugs manufactured abroad will be enforced unless countries negotiate lower rates or companies commit to building production facilities in the United States. Large pharmaceutical companies will have 120 days to submit their reshoring plans, while smaller firms will have 180 days. The tariffs aim to boost domestic manufacturing and combat alleged price manipulation by foreign entities. Additionally, the new metal duties will apply a 25% tariff on finished goods containing significant amounts of steel, aluminum, and copper, simplifying the previous system. Although officials assert that these tariffs will not affect consumer prices, concerns remain ahead of the upcoming midterm elections. Countries such as the European Union, Japan, South Korea, and Switzerland are exempt from the full tariffs due to existing trade agreements, while the UK has secured a three-year tariff-free access for its medicines.